INT129695

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2005
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 6
Total Number 10
Disease Relevance 4.96
Pain Relevance 2.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transmembrane transporter activity (Sv2a) endoplasmic reticulum (Sv2a) cytoplasm (Sv2a)
Anatomy Link Frequency
synaptic vesicle 3
plasma 2
SV2A 2
TGNs 1
spinal cord 1
Sv2a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Central nervous system 20 100.00 Very High Very High Very High
Spinal cord 5 99.52 Very High Very High Very High
Potency 8 98.00 Very High Very High Very High
gABA 46 96.16 Very High Very High Very High
Calcium channel 32 93.80 High High
antiepileptic Drug 136 92.16 High High
Calcitonin gene-related peptide 5 88.04 High High
Neurotransmitter 2 86.96 High High
qutenza 2 85.76 High High
antagonist 3 74.20 Quite High
Disease Link Frequency Relevance Heat
Convulsion 646 98.62 Very High Very High Very High
Targeted Disruption 4 98.10 Very High Very High Very High
Reflex Epilepsy 4 97.40 Very High Very High Very High
Epilepsy 394 97.28 Very High Very High Very High
Syndrome 306 95.48 Very High Very High Very High
Toxicity 6 92.08 High High
Partial Seizures 72 88.56 High High
Nociception 3 86.36 High High
Hepatic Insufficiency 2 83.80 Quite High
Generalized Epilepsy 42 80.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.
synaptic vesicle protein 2A Binding (binding) of in spinal cord associated with spinal cord
1) Confidence 0.47 Published 2005 Journal Eur. J. Pharmacol. Section Title Doc Link 16125696 Disease Relevance 0.05 Pain Relevance 0.20
The exact role of the SV2A protein is not fully understood; it is thought to participate in the physiologic functioning of the synaptic vesicle.19 Its role in epilepsy is supported by the fact that SV2A knock-out mice develop seizures soon after birth and usually die within 3 weeks.21 Furthermore, the affinity of various compounds to the SV2A binding site correlates strongly with their anti-seizure potency in the audiogenic epilepsy mouse model.19


SV2A Binding (affinity) of in SV2A associated with targeted disruption, epilepsy, convulsion, reflex epilepsy and potency
2) Confidence 0.37 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2747386 Disease Relevance 0.49 Pain Relevance 0.20
The exact role of the SV2A protein is not fully understood; it is thought to participate in the physiologic functioning of the synaptic vesicle.19 Its role in epilepsy is supported by the fact that SV2A knock-out mice develop seizures soon after birth and usually die within 3 weeks.21 Furthermore, the affinity of various compounds to the SV2A binding site correlates strongly with their anti-seizure potency in the audiogenic epilepsy mouse model.19


SV2A Binding (binding) of in SV2A associated with targeted disruption, epilepsy, convulsion, reflex epilepsy and potency
3) Confidence 0.37 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2747386 Disease Relevance 0.49 Pain Relevance 0.19
Early work by Noyer et al suggested a protein-binding site that was highly specific to central nervous system (CNS) synaptic plasma membranes.6 More recently, that site was identified by Lynch et al as the synaptic vesicle protein 2A (SV2A), a plasma membrane protein of approximately 90kDa that is nearly ubiquitous throughout the CNS. 19 Levetiracetam binds reversibly, saturably, and stereo-specifically to this receptor site.6,15,19,20
SV2A Binding (binds) of in plasma associated with central nervous system
4) Confidence 0.35 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2747386 Disease Relevance 0.41 Pain Relevance 0.38
Early work by Noyer et al suggested a protein-binding site that was highly specific to central nervous system (CNS) synaptic plasma membranes.6 More recently, that site was identified by Lynch et al as the synaptic vesicle protein 2A (SV2A), a plasma membrane protein of approximately 90kDa that is nearly ubiquitous throughout the CNS. 19 Levetiracetam binds reversibly, saturably, and stereo-specifically to this receptor site.6,15,19,20
synaptic vesicle protein 2A Binding (binds) of in plasma associated with central nervous system
5) Confidence 0.35 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2747386 Disease Relevance 0.46 Pain Relevance 0.38
Whether LEV’s binding at SV2A proteins mediates these mechanisms is unknown (Lynch et al 2004).
SV2A Spec (Whether) Binding (binding) of
6) Confidence 0.33 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2655081 Disease Relevance 0.60 Pain Relevance 0.17
Seletracetam (SEL) is another new pyrrolidone derivative structurally related to LEV (Bennet et al 2007; Bialer et al 2007), discovered because of its high binding affinity to the synaptic vesicle 2A (SV2A) protein.
SV2A Binding (affinity) of in synaptic vesicle
7) Confidence 0.25 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.73 Pain Relevance 0.06
LEV binds to a unique binding site in the brain, the synaptic vesicle protein SV2A.
SV2A Binding (binds) of in synaptic vesicle
8) Confidence 0.21 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2655081 Disease Relevance 0.68 Pain Relevance 0.21
Brivaracetam (BRI) possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) that is ten-fold more powerful than LEV and also shows an ability to inhibit Na+ channels.
SV2A Binding (affinity) of in synaptic vesicle
9) Confidence 0.18 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.71 Pain Relevance 0.08
It bound effectively to the C isoform of SV2 abundantly expressed in TGNs and cleaved SNAP-25, indicating that its /A binding domain (H(C)) mediated uptake of the active /E protease.
SV2 Binding (bound) of in TGNs
10) Confidence 0.04 Published 2009 Journal J. Neurosci. Section Abstract Doc Link 19369567 Disease Relevance 0.34 Pain Relevance 0.64

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox